Ginza Cancer Medical Clinic, located in Ginza, Chuo-ku, Tokyo, is an internal medicine clinic specializing in "dendritic cell therapy using tuberculosis bacteria" developed by researchers at Osaka University School of Medicine. The dendritic cell therapy adopted by this clinic is an immunotherapy with over 30 years of treatment track record since the 1970s, characterized by fewer side effects compared to chemotherapy. Since it can be received in parallel with standard treatments such as anticancer drug therapy and surgery, it serves as an option for patients who wish to strengthen their immune system while continuing their existing treatment. The clinic primarily targets patients with terminal cancer, refractory cancers, or those exploring other treatment options, and emphasizes healthcare delivery focused on improving QOL (Quality of Life). The attending physician completed graduate studies at Iwate Medical University, engaged in cancer chemotherapy research at Tokyo Medical University Hospital, and has experience conducting investigator-initiated clinical trials of dendritic cell therapy with physicians at Osaka University. Consultation hours are from 10:00 AM to 2:00 PM and 4:00 PM to 7:00 PM, and the clinic accepts credit cards and electronic payments, ensuring convenience in payment.